Objectives: Periorbital microcystic lymphatic malformations (LM) can cause severe symptoms, such as blepharoptosis, amblyopia, chemosis, strabismus, diminished vision, and blindness. The purpose of this study was to evaluate the clinical outcome in periorbital microcystic LM patients with blepharoptosis who underwent surgical treatment combined with intralesional bleomycin injection.
Patients And Methods: A retrospective study including nine patients diagnosed as periorbital microcystic LM with blepharoptosis was conducted. All of the patients underwent surgical treatment and bleomycin injection from January 2010 to January 2014. The lesion was resected through the lower eyebrow and/or a coronal incision at the first stage, and levator resection was performed at the second stage. Any persistent lesion or its recurrence was managed by intralesional bleomycin injection.
Results: Blepharoptosis and visual obstruction were corrected in all patients. Mean follow-up was 24.6 months. Six patients had recurrence during the follow-up, and two patients who had partial eyelid closure after the second stage surgery recovered in three months. Amblyopia, astigmatism, and strabismus were not improved after treatment. All of the patients had excellent aesthetic improvement and corrected blepharoptosis.
Conclusions: Resection through a lower eyebrow and coronal incision and levator resection performed in two stages can quickly correct the visual impairment caused by periorbital microcystic lymphatic malformation with blepharoptosis. Intralesional bleomycin injection is a promising adjunctive therapy for residual or recurrent lesions after surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpedsurg.2014.12.011 | DOI Listing |
Ophthalmic Plast Reconstr Surg
December 2024
Department of Ophthalmology, Liverpool Hospital, Liverpool, New South Wales.
Purpose: Microcystic adnexal carcinoma (MAC) is a locally aggressive adnexal carcinoma of the head and neck, which has a high tendency for recurrence. MAC rarely has distant metastasis, with only one previously reported case originating from the periorbital region. We present a patient with periorbital MAC with distant metastasis and a review of all reported patients with metastatic disease.
View Article and Find Full Text PDFEur J Ophthalmol
November 2023
Hong Kong Eye Hospital, Hong Kong Special Administrative Region.
Purpose: To describe and report the outcomes of doxycycline sclerotherapy in patients with periorbital lymphatic malformations(LMs).
Basic Procedures: A retrospective review of consecutive patients diagnosed with periorbital LMs and who received doxycycline sclerotherapy at Hong Kong Eye Hospital and Queen Elizabeth Hospital, Hong Kong between January 2016 and June 2022. Doxycycline was prepared with a concentration of 100 mg diluted in 10 mL water for injection.
Orbit
April 2024
Division of Ophthalmology, Warren Alpert Medical School of Brown University, Providence, RI, USA.
Ruxolitinib is an oral Janus associated kinase (JAK) inhibitor commonly used in the treatment of primary myelofibrosis. We describe a case of an 86-year-old woman on ruxolitinib for primary myelofibrosis who presented with a three-day history of worsening left eyelid swelling, pain, and decreased vision. Her exam was notable for left upper lid ptosis, periorbital edema, and nearly complete external ophthalmoplegia along with diffuse conjunctival injection and microcystic corneal edema.
View Article and Find Full Text PDFCardiovasc Intervent Radiol
March 2019
Department of Ophthalmology, Cairo University Hospitals, Cairo, Egypt.
Purpose: To evaluate the effectiveness and safety of image-guided percutaneous sclerotherapy using bleomycin for macrocystic and bevacizumab (Avastin™) for microcystic orbital lymphatic malformations in children.
Materials And Methods: Between October 2015 and July 2018, we prospectively evaluated 10 pediatric patients who presented clinically and radiologically with lymphatic malformations and were treated with percutaneous sclerotherapy. Patients with venous malformations were excluded.
J Pediatr Surg
August 2015
Department of Plastic Surgery, Shanghai 9th People's Hospital, Shanghai Jiaotong University, School of Medicine.
Objectives: Periorbital microcystic lymphatic malformations (LM) can cause severe symptoms, such as blepharoptosis, amblyopia, chemosis, strabismus, diminished vision, and blindness. The purpose of this study was to evaluate the clinical outcome in periorbital microcystic LM patients with blepharoptosis who underwent surgical treatment combined with intralesional bleomycin injection.
Patients And Methods: A retrospective study including nine patients diagnosed as periorbital microcystic LM with blepharoptosis was conducted.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!